110683-71-1

Upstream product

• 5274-70-4 3-nitrosalicylic aldehyde 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 935758-15-9 3-oxo-3,4-dihydro-2H-1,4-benzoxazine-8-carbaldehyde 
• 1233706-52-9 C₉H₇NO₄ 
• 1233706-54-1 C₉H₉NO₄ 
• 110683-72-2 ethyl 7-nitrobenzofuran-2-carboxylate 

Relevant academic research and scientific papers

Development of an efficient large-scale synthesis for a 4 H-imidazo[5,1- c ][1,4]benzoxazine-3-carboxamide derivative for depression and anxiety

The development and scale-up of an optimized synthesis for a novel drug candidate for depression and anxiety is presented. The updated synthesis represents a convergent and efficient four-stage approach to the API, overcoming high cost of goods (COG), gen

New potent antagonists of leukotrienes C4 and D4. 1. Synthesis and structure-activity relationships

(p-Amylcinnamoyl)anthranilic acid (3a) had moderate antagonist activities against LTD4-induced smooth muscle contraction on guinea pig ileum and LTC4-induced bronchoconstriction in anesthetized guinea pigs. Modifications were made in the hydrophobic part (cinnamoyl moiety) and the hydrophilic part (anthranilate moiety) of 3a. A series of 8-(benzoylamino)-2-tetrazol-5-yl-1,4-benzodioxans and 8-(benzoylamino)-2-tetrazol-5-yl-4-oxo-4H-1-benzopyrans were revealed to be potent antagonists of leukotrienes C4 and D4. Among both series, ONO-RS-347 (18k) and ONO-RS411 (19h) were the most potent and orally active antagonists, respectively. Structure-activity relationships are discussed.